Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study will recruit 316 ischemic stroke patients taking aspirin.
They will be randomly assigned into cilostazol group or placebo group. Every patients will
take 200mg of cilostazol a day or placebo for 1 month.
The primary outcome variable of this study is rate of biochemical aspirin resistance on the
Ultra Rapid Platelet Function Assay-ASA.